TY  - GEN
AU  - Masmiquel Comas, Lluis
AU  - Leiter, LA
AU  - Vidal, J
AU  - Bain, S
AU  - Petrie, J
AU  - Franek, Edward
AU  - Raz, I
AU  - Comlekci, A
AU  - Jacob, S
AU  - van Gaal, L
AU  - Baeres, F. M. M
AU  - Marso, SP
AU  - Eriksson, M
AU  - LEADER Investigators
PY  - 2016
DO  - 10.1186/s12933-016-0341-5
UR  - http://hdl.handle.net/20.500.12105/20248
AB  - Background: Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the baseline data of liraglutide effect and action in diabetes: evaluation of CV outcome...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Liraglutide
KW  - Cardiovascular
KW  - Type 2 diabetes
KW  - LEADER
KW  - Cardiometabolic
KW  - Obesity
KW  - Overweight
KW  - Cardiovascular Diseases
KW  - Diabetes Mellitus, Type 2
KW  - Metabolic Syndrome
TI  - LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
TY  - research article
ER  -